These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 17641000)
21. Conversion of thyrotropin heterodimer to a biologically active single-chain. Fares FA; Yamabe S; Ben-Menahem D; Pixley M; Hsueh AJ; Boime I Endocrinology; 1998 May; 139(5):2459-64. PubMed ID: 9564858 [TBL] [Abstract][Full Text] [Related]
22. Localization of an essential ligand binding determinant of the human erythropoietin receptor to a domain N-terminal to the WSXWS motif: implications for soluble receptor function. Schimmenti LA; Blechert G; Harris KW; Winkelmann JC Exp Hematol; 1995 Dec; 23(13):1341-6. PubMed ID: 7498361 [TBL] [Abstract][Full Text] [Related]
23. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. Savino C; Pedotti R; Baggi F; Ubiali F; Gallo B; Nava S; Bigini P; Barbera S; Fumagalli E; Mennini T; Vezzani A; Rizzi M; Coleman T; Cerami A; Brines M; Ghezzi P; Bianchi R J Neuroimmunol; 2006 Mar; 172(1-2):27-37. PubMed ID: 16337691 [TBL] [Abstract][Full Text] [Related]
24. Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice. Yang J; Sun J; Castellanos DM; Pardridge WM; Sumbria RK Mol Pharm; 2020 Aug; 17(8):2831-2839. PubMed ID: 32579360 [TBL] [Abstract][Full Text] [Related]
25. Development and biological activity of long-acting recombinant human interferon-α2b. Zhang Q; Wang C; Ma F; Yao L; Gao H; Zhu L; Zheng L BMC Biotechnol; 2020 Mar; 20(1):16. PubMed ID: 32169063 [TBL] [Abstract][Full Text] [Related]
26. Conversion of TSH heterodimer to a single polypeptide chain increases bioactivity and longevity. Azzam N; Bar-Shalom R; Fares F Endocrinology; 2012 Feb; 153(2):954-60. PubMed ID: 22234466 [TBL] [Abstract][Full Text] [Related]
27. Production of a therapeutic protein by fusing it with two fragments of the carboxyl-terminal peptide of human chorionic gonadotropin β-subunit in Pichia pastoris. Wang B; Wang X; Wayne C; Wang X; Han L; Ye L; Zhao Q; Jiang G; Feng M Biotechnol Lett; 2016 May; 38(5):801-7. PubMed ID: 26830094 [TBL] [Abstract][Full Text] [Related]
28. Highly sialylated recombinant human erythropoietin production in large-scale perfusion bioreactor utilizing CHO-gmt4 (JW152) with restored GnT I function. Goh JS; Liu Y; Liu H; Chan KF; Wan C; Teo G; Zhou X; Xie F; Zhang P; Zhang Y; Song Z Biotechnol J; 2014 Jan; 9(1):100-9. PubMed ID: 24166780 [TBL] [Abstract][Full Text] [Related]
29. Control of rHuEPO biological activity: the role of carbohydrate. Elliott S; Egrie J; Browne J; Lorenzini T; Busse L; Rogers N; Ponting I Exp Hematol; 2004 Dec; 32(12):1146-55. PubMed ID: 15588939 [TBL] [Abstract][Full Text] [Related]
30. Physician Education: The Erythropoietin Receptor and Signal Transduction. Yoshimura A; Arai K Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012 [TBL] [Abstract][Full Text] [Related]
31. The carboxyl-terminal region is a determinant for the intracellular behavior of the chorionic gonadotropin beta subunit: effects on the processing of the Asn-linked oligosaccharides. Muyan M; Boime I Mol Endocrinol; 1998 May; 12(5):766-72. PubMed ID: 9605938 [TBL] [Abstract][Full Text] [Related]
32. Glycoprotein hormone structure-function and analog design. Boime I; Ben-Menahem D Recent Prog Horm Res; 1999; 54():271-88; discussion 288-9. PubMed ID: 10548880 [TBL] [Abstract][Full Text] [Related]
34. Effect of chronic and short-term erythropoietin treatment on random flap survival in rats: an experimental study. Saray A; Ozakpinar R; Koc C; Serel S; Sen Z; Can Z Laryngoscope; 2003 Jan; 113(1):85-9. PubMed ID: 12514388 [TBL] [Abstract][Full Text] [Related]
35. Structural and biological properties of erythropoietin in Xenopus laevis. Nogawa-Kosaka N; Hirose T; Kosaka N; Aizawa Y; Nagasawa K; Uehara N; Miyazaki H; Komatsu N; Kato T Exp Hematol; 2010 May; 38(5):363-72. PubMed ID: 20193733 [TBL] [Abstract][Full Text] [Related]
36. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis]. Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643 [TBL] [Abstract][Full Text] [Related]
37. Post-translational modification of a chimeric EPO-Fc hormone is more important than its molecular size in defining its in vivo hematopoietic activity. Salgado ER; Montesino R; Jiménez SP; González M; Hugues F; Cabezas OI; Maura-Perez R; Saavedra P; Lamazares E; Salas-Burgos A; Vera JC; Sánchez O; Toledo JR Biochim Biophys Acta; 2015 Sep; 1850(9):1685-93. PubMed ID: 25960389 [TBL] [Abstract][Full Text] [Related]
38. Human thyrotropin (TSH) variants designed by site-directed mutagenesis block TSH activity in vitro and in vivo. Azzam N; Bar-Shalom R; Kraiem Z; Fares F Endocrinology; 2005 Jun; 146(6):2845-50. PubMed ID: 15761043 [TBL] [Abstract][Full Text] [Related]
39. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. Boado RJ; Hui EK; Lu JZ; Pardridge WM J Pharmacol Exp Ther; 2010 Jun; 333(3):961-9. PubMed ID: 20233799 [TBL] [Abstract][Full Text] [Related]
40. [Expression of rhEPO-L-Fc fusion protein and analysis of its bioactivity and pharmacokinetics]. Zhu Q; Huang Z; Huang Y; Qin Y Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1874-9. PubMed ID: 19256332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]